guanfacine has been researched along with Autism Spectrum Disorder in 10 studies
Guanfacine: A centrally acting antihypertensive agent with specificity towards ADRENERGIC ALPHA-2 RECEPTORS.
Autism Spectrum Disorder: Wide continuum of associated cognitive and neurobehavioral disorders, including, but not limited to, three core-defining features: impairments in socialization, impairments in verbal and nonverbal communication, and restricted and repetitive patterns of behaviors. (from DSM-V)
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a prior report, we showed that extended-release guanfacine (GEXR) is safe and effective for children with autism spectrum disorder (ASD) accompanied by ADHD symptoms." | 9.27 | A randomized, placebo-controlled trial of extended-release guanfacine in children with autism spectrum disorder and ADHD symptoms: an analysis of secondary outcome measures. ( Figueroa, J; King, B; McCracken, JT; McDougle, CJ; Politte, LC; Scahill, L, 2018) |
| "Four guanfacine-treated subjects (13." | 6.80 | Extended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum Disorder. ( Cowen, J; Deng, Y; Dziura, J; King, BH; Loo, S; McCracken, JT; McDougle, CJ; Minjarez, M; Mullett, J; Page, C; Politte, L; Rockhill, C; Sanders, R; Scahill, L; Shah, B; Ward, D, 2015) |
| "In a prior report, we showed that extended-release guanfacine (GEXR) is safe and effective for children with autism spectrum disorder (ASD) accompanied by ADHD symptoms." | 5.27 | A randomized, placebo-controlled trial of extended-release guanfacine in children with autism spectrum disorder and ADHD symptoms: an analysis of secondary outcome measures. ( Figueroa, J; King, B; McCracken, JT; McDougle, CJ; Politte, LC; Scahill, L, 2018) |
| " (2020) present a systematic review with meta-analyses that reports the efficacy of five treatments for children with attention-deficit hyperactivity disorder symptoms in the context of autism spectrum disorder - (a) methylphenidate; (b) atomoxetine; (c) guanfacine; (d) aripiprazole; and (e) risperidone." | 4.02 | Commentary: Identifying individualized predictions of response in ADHD pharmacotherapy - a commentary on Rodrigues et al. (2020). ( Bloch, MH; Farhat, LC, 2021) |
| "Four guanfacine-treated subjects (13." | 2.80 | Extended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum Disorder. ( Cowen, J; Deng, Y; Dziura, J; King, BH; Loo, S; McCracken, JT; McDougle, CJ; Minjarez, M; Mullett, J; Page, C; Politte, L; Rockhill, C; Sanders, R; Scahill, L; Shah, B; Ward, D, 2015) |
| "Methylphenidate was associated with a nonsignificant elevated risk of dropout due to adverse events." | 2.72 | Practitioner Review: Pharmacological treatment of attention-deficit/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: a systematic review and meta-analysis. ( Ameis, SH; Anagnostou, E; Anderson, KK; Beswick, A; Gorman, DA; Lai, MC; Rodrigues, R; Szatmari, P, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 3 (30.00) | 2.80 |
| Authors | Studies |
|---|---|
| de Groof, C | 1 |
| De La Marche, W | 1 |
| Danckaerts, M | 1 |
| Rodrigues, R | 1 |
| Lai, MC | 1 |
| Beswick, A | 1 |
| Gorman, DA | 1 |
| Anagnostou, E | 1 |
| Szatmari, P | 1 |
| Anderson, KK | 1 |
| Ameis, SH | 1 |
| Joshi, G | 1 |
| Wilens, T | 1 |
| Firmin, ES | 1 |
| Hoskova, B | 1 |
| Biederman, J | 1 |
| Farhat, LC | 1 |
| Bloch, MH | 1 |
| Naguy, A | 1 |
| Howes, OD | 1 |
| Rogdaki, M | 1 |
| Findon, JL | 1 |
| Wichers, RH | 1 |
| Charman, T | 1 |
| King, BH | 2 |
| Loth, E | 1 |
| McAlonan, GM | 1 |
| McCracken, JT | 3 |
| Parr, JR | 1 |
| Povey, C | 1 |
| Santosh, P | 1 |
| Wallace, S | 1 |
| Simonoff, E | 1 |
| Murphy, DG | 1 |
| Politte, LC | 1 |
| Scahill, L | 2 |
| Figueroa, J | 1 |
| King, B | 1 |
| McDougle, CJ | 2 |
| Propper, L | 1 |
| Rockhill, C | 1 |
| Shah, B | 1 |
| Politte, L | 1 |
| Sanders, R | 1 |
| Minjarez, M | 1 |
| Cowen, J | 1 |
| Mullett, J | 1 |
| Page, C | 1 |
| Ward, D | 1 |
| Deng, Y | 1 |
| Loo, S | 1 |
| Dziura, J | 1 |
| Emslie, GJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of Pharmacologic Management of ADHD in Children and Youth With Autism Spectrum Disorder[NCT05916339] | Phase 4 | 500 participants (Anticipated) | Interventional | 2023-10-01 | Not yet recruiting | ||
| A Multi-Center, Open Label, Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder[NCT03337646] | Phase 4 | 48 participants (Actual) | Interventional | 2018-09-26 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for guanfacine and Autism Spectrum Disorder
| Article | Year |
|---|---|
[Effectiveness of guanfacin on comorbid disorders in children and adolescents with adhd: a systematic literature review].
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Anxiety Disorders; Attention Deficit Disorder with | 2019 |
Practitioner Review: Pharmacological treatment of attention-deficit/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: a systematic review and meta-analysis.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Autism Spectru | 2021 |
Pharmacotherapy of attention deficit/hyperactivity disorder in individuals with autism spectrum disorder: A systematic review of the literature.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; | 2021 |
Autism spectrum disorder: Consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology.
Topics: Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Autism Spectrum D | 2018 |
2 trials available for guanfacine and Autism Spectrum Disorder
| Article | Year |
|---|---|
A randomized, placebo-controlled trial of extended-release guanfacine in children with autism spectrum disorder and ADHD symptoms: an analysis of secondary outcome measures.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; Child; Child, P | 2018 |
Extended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum Disorder.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Autism Spectrum Disorder; Child; Child, Preschool; | 2015 |
Extended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum Disorder.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Autism Spectrum Disorder; Child; Child, Preschool; | 2015 |
Extended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum Disorder.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Autism Spectrum Disorder; Child; Child, Preschool; | 2015 |
Extended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum Disorder.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Autism Spectrum Disorder; Child; Child, Preschool; | 2015 |
4 other studies available for guanfacine and Autism Spectrum Disorder
| Article | Year |
|---|---|
Commentary: Identifying individualized predictions of response in ADHD pharmacotherapy - a commentary on Rodrigues et al. (2020).
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; | 2021 |
Pharmacotherapy of Attention Deficit Hyperactivity Disorder Symptom Profile in ASD.
Topics: Aripiprazole; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Autism Spect | 2017 |
Managing disruptive behaviour in autism-spectrum disorder with guanfacine.
Topics: Adrenergic alpha-2 Receptor Agonists; Aggression; Autism Spectrum Disorder; Child; Delayed-Action Pr | 2018 |
Pediatric Psychopharmacology Trials: Beyond Efficacy.
Topics: Adrenergic alpha-2 Receptor Agonists; Autism Spectrum Disorder; Delayed-Action Preparations; Female; | 2015 |